Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have
recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the
growth of tumor cells by blocking the enzymes necessary for tumor cell growth.